Pharmaceutical major Cipla said on Wednesday that its net profit for the second quarter of 2016-17 dropped by 35 per cent to Rs 354 crore compared to Rs 543 crore posted during the corresponding quarter in 2015-16.
In a regulatory filing, the company said that it posted a total income of Rs 3,751 crore from operations in the quarter compared to Rs 3,455 crore posted during the same period a year ago.
"The performance reflects improvement in the quality of the base business, endorsing our strategic intent of investing in the future through increased research and development efforts. We continue to stay focused on building operational efficiencies and strengthening our presence in priority markets," said Umang Vohra, MD and Global CEO, Cipla.--IANS
ag/vd
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app